TME Pharma N.V. announced that it successfully completed its pre-IND advice meeting with the US regulator, the Food and Drug Administration (FDA), discussing plans for the further clinical development of NOX-A12 as a treatment of aggressive adult brain cancer, glioblastoma. Based on the feedback received, TME Pharma confirms that it is on track with preparations to file its Investigational New Drug (IND) application and the expedited regulatory pathway request on a timeline that will allow successful completion of both by the end of First Quarter 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.249 EUR | +0.20% | -0.99% | +8.26% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.26% | 7.56M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALTME Stock
- News TME Pharma N.V.
- TME Pharma Announces Successful Advice Meeting with US Food and Drug Administration on Nox-A12 Development in Brain Cancer